The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution Update

27 Jun 2005 06:00

Embargoed: 27 June 2004 Akers Biosciences, Inc. ("Akers" or the "Company") Re. UK Distribution Agreement Akers Biosciences, Inc. is pleased to announce the launch of a number of itsproducts in the UK through its UK distribution agent Advanced Rapid DiagnosticsLimited ("ARD"). ARD was established in order to penetrate the UK markets withAkers' growing range of products.The Company is already actively marketing a number of CE approved products inthe UK through ARD which, among others, include:Tests for `drugs of abuse'Akers has developed a suite of tests for `drugs of abuse' including tests foruse of methadone, heroine, cocaine, marijuana and ecstasy among others. Forthis product ARD is targeting the public service markets alongside retailbusinesses or, indeed, any organisation wishing to have the ability to performrapid tests on staff. The Company believes that there is significant potentialfor law enforcement agencies or educational establishments to adopt thesetests.Alcohol BreathalyzersARD is marketing Akers' range of alcohol breathalyzers in the UK to a range ofindustries, in particular transport businesses operating any form of vehicles,be they rail, air, road or sea. In addition to ensuring transportation safety,the use of these products may also positively impact insurance costs for thesebusinesses. ARD will also be looking to penetrate retail markets including highstreet pharmacies so that the public will have access to affordable tests toshow alcohol levels, with particular emphasis on self-regulation in the case ofdriving.PIFA‚® Heparin/PF4 test for heparin-induced thrombocytopenia and thrombosissyndrome (HITTS)Following increasing levels of penetration in the United States and Canada forthis test, the first rapid test for heparin/platelet factor-4 antibodies, ARDwill be initially targeting the private healthcare sector in the UK. Heparin isa widely used intravenous anticoagulant in the United Kingdom. Intravenousheparin is commonly used for the prophylaxis and treatment of thromboembolicdisease, as well as numerous other applications including certain types of lungand heart disorders, and during or after a variety of surgeries including openheart, bypass, dialysis and orthopedic procedures. Heparin is also used fordiagnostic and therapeutic interventional radiologic procedures. Akers' test isable to identify, almost instantly, patients at risk for developing HITTS as aresult of administering of heparin. This is particularly crucial in cases ofemergency surgery. Patients identified by the test as being at risk can beprescribed alternative drugs in order to avoid, potentially, fatal reactions toheparin.Cholesterol TestsBlood cholesterol consists of HDL cholesterol (often called "good cholesterol")and LDL cholesterol (often called "bad cholesterol"). The risk of heart diseaseis related to HDL levels, total cholesterol levels, and other risk factors. TheAkers Biosciences Tri-Cholesterol Test Kit is the only FDA-approved rapid assaythat provides a complete cholesterol profile of the patient, withsemi-quantitative determinations of high-density lipoprotein (HDL) cholesterol,low-density lipoprotein (LDL) cholesterol, and total cholesterol levels inwhole blood obtained from a finger stick. The test is designed for routinemonitoring of cholesterol levels right in a physician's office or directly athome.Dr. Raymond Akers, Chief Executive, Akers Biosciences, Inc. commented,"We are now enjoying very encouraging levels of sales for many of our productsin the United States and other parts of the world and I am delighted to beembarking upon an aggressive marketing and sales drive in the UK. As is thecase in the US, many of our products will be completely unique in the UK,enabling crucial tests to be performed rapidly and accurately. There is agrowing need for tests for alcohol levels and use of drugs of abuse all overthe world. Our tests in this area will enable people, particularly in thetransport and education industries to identify situations of abuse instantly.As for our PIFA Heparin PF-4 test, we believe this test will help save lives inthe UK. In addition, the medical industry can save millions of pounds inheparin-related law suits of patients who have suffered symptoms of a drugwhose prescription could have been avoided through identification of risk withour test and the prescription of an alternative."Dr. Raymond AkersChief Executive, Akers Biosciences, Inc.Tel. 020 7917 9476Barry ParkerChief Executive, Advanced Rapid Diagnostics LimitedTel. 0161 792 1112Ben SimonsHansard CommunicationsTel. 020 7245 1100ENDAKERS BIOSCIENCES INC
Date   Source Headline
14th Jul 20177:00 amRNSNotice of AGM & Directorate Changes
3rd Jul 20172:53 pmRNSForm S-3 Registration Statement
9th Jun 20174:51 pmRNSIssue of Equity
16th May 20177:00 amRNS1st Quarter Results
12th May 20172:30 pmRNSNotice of Q1 Results
5th May 201710:53 amRNSIssue of Equity
24th Apr 20175:12 pmRNSIssue of Equity
11th Apr 20179:13 amRNSHolding(s) in Company
11th Apr 20177:00 amRNSFinal Results
10th Apr 20173:00 pmRNSNotice of Results
10th Apr 201712:00 pmRNSIssue of Equity
10th Apr 20177:00 amRNSHeparin PF4 Rapid Test in Puerto Rico
6th Apr 20175:39 pmRNSIssue of Equity
4th Apr 20174:18 pmRNSIssue of Equity
31st Mar 20177:00 amRNSIssue of Equity
30th Mar 20171:30 pmRNSDetailed Year-end Trading Update
29th Mar 20177:00 amRNSNotice of Results
28th Mar 201712:00 pmRNSInitial Order for Rapid Cholesterol Self-test
16th Feb 20177:00 amRNSUS Patent for Akers Wellness Tests Cartridge
1st Feb 20177:00 amRNSTrading Update
13th Jan 20177:00 amRNSIssue of Equity
10th Jan 20177:00 amRNSIssue of Equity
9th Jan 20177:00 amRNSSupplement to Form S-3 Registration Statement
19th Dec 20165:00 pmRNSResult of AGM
19th Dec 20167:00 amRNSAgreement with GNYHA for PIFA Heparin PF4 Test
1st Dec 201612:00 pmRNSUS Distribution Agreement: Cholesterol Self-test
28th Nov 20167:06 amRNSClinical Trial for BreathScan DKA Completed
17th Nov 20167:00 amRNSSupplement to Form S-3 Registration Statement
14th Nov 201612:00 pmRNSNotice of AGM
14th Nov 20167:00 amRNS3rd Quarter Results
10th Nov 20167:00 amRNSEuropean Patent Granted
9th Nov 20164:29 pmRNSNotice of Q3 Results
25th Oct 20167:00 amRNSFiling of Form S-3 Registration Statement
19th Aug 20167:00 amRNSSettlement of Dispute with ChubeWorkx
18th Aug 20167:00 amRNSResults of OxiChek Test Study
11th Aug 20167:00 amRNSHalf Yearly Results
9th Aug 20164:00 pmRNSNotice of H1 2016 Earnings
30th Jun 20167:00 amRNSClinical Trial for Rapid Chlamydia Test Completed
27th Jun 20167:00 amRNSDistribution Agreement for BreathScan OxiChekT
14th Jun 201612:00 pmRNSIssue of Equity & PDMR Shareholding
26th May 20165:10 pmRNSPDMR Shareholding
12th May 20167:00 amRNSFinancial Results for Q1 2016
10th May 201612:00 pmRNSNotice of Q1 Results
25th Apr 201612:00 pmRNSBoard Rearrangement
30th Mar 20167:00 amRNSFinal Results
23rd Mar 20167:00 amRNSUS Patent - Heparin/PF4 Antibody Detection
16th Mar 20167:00 amRNSNotice of Results
2nd Mar 20167:00 amRNS$2.5M Product Order
29th Feb 20167:00 amRNSSenior Commercial Team Appointments
6th Jan 20167:00 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.